Immunomodulatory therapies delay disease progression in multiple sclerosis

Conclusions:
DMDs significantly reduce the risk of multiple sclerosis progression both in patients with initial high-risk and patients with initial low-risk. These findings reinforce the role of DMDs in modifying the natural course of the disease, suggesting that they have a positive effect not only on the inflammatory but also on the neurodegenerative process. The study also confirms the capability of the BREMS score to predict MS evolution.

Source: Multiple Sclerosis - November 3, 2016 Category: Neurology Authors: Bergamaschi, R., Quaglini, S., Tavazzi, E., Amato, M. P., Paolicelli, D., Zipoli, V., Romani, A., Tortorella, C., Portaccio, E., DOnghia, M., Garberi, F., Bargiggia, V., Trojano, M. Tags: Original Research Papers Source Type: research